Ductal carcinoma in situ and the extent of surgery

Česká verzia

Authors: J. Gatěk ^1,4 ; V. Petrů ¹; P. Kosáč ¹; P. Vážan ²; M. Zábojníková ³; M. Ratajský ¹; B. Dudešek ¹; P. Holík ⁴; K. Lajmar ¹; P. Jančík ¹; J. Duben ¹
Authors place of work: Chirurgické oddělení EUC Klinika Zlín ¹; Cytologická laboratoř CGB Zlín ²; Onkologické oddělení KTNB Zlín ³; Univerzita Tomáše Bati ve Zlíně ⁴
Published in the journal: Rozhl. Chir., 2021, roč. 100, č. 4, s. 166-172.
Category: Original articles
doi: https://doi.org/10.33699/PIS.2021.100.4.

Summary

Introduction: Ductal carcinoma in situ (DCIS) is a very heterogenous disease. The incidence of DCIS has been increasing with the adoption of mammography screening. This opened new questions concerning surgical and adjuvant therapy.

Methods: We retrospectively observed the incidence of DCIS amongst the patients that underwent surgical resection in EUC clinic Zlín between 2017 and 2019. We also assessed the extent of breast surgery including interventions in axilla and the adjuvant therapy.

Results: There were 616 breast cancer patients, of whom 44 (7.1%) were diagnosed with DCIS. Breast-conserving surgery was performed in 35 (80%) patients. Lumpectomy alone was performed in 21 (47%) patients. Mastectomy was indicated primarily in 9 cases with additional two mastectomies performed to achieve clear margins. All sentinel nodes were negative.

Conclusion: Results confirmed, that the surgical therapy as well as radiotherapy and hormonal treatment are performed according to guidelines at our department. Proportion of sentinel node biopsy is remarkably higher, therefore an improvement in this area is our next goal.

Keywords:

DCIS – breast-conserving surgery − sentinel node − local recurrence

Zdroje

Choi D, Van Zee K, Memorial Sloan-Kettering Cancer Center: two decades of experience with ductal carcinoma in situ of the breast. Int J Surg Oncol. 2012;(3):723916. doi: 10.1155/2012/723916.
DeSnyder S, Hunt K, Dong W, et al. American Society of Breast Surgeons’ practice patterns after publication of the SSO-ASTRO-ASCO DCIS consensus guideline on margins for breast-conserving surgery with whole-breast irradiation. Ann Surg Oncol. 2018;(25):2965−2974;(10):2965−2974. doi:10.1245/s10434-018-6580-9.
Rojas K, Fortes T, Borgen P. Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy. Breast Cancer Research and Treatment 2019;(174):307−313. doi:10.1007/s10549-018-05080-0.
Marinovich M, Azizi L, Macaskill P, et al. The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis. Ann Surg Oncol. 2016;(23):3811−3821. doi:10.1245/s10434-016-5446-2.
Morrow M, Katz S. Addressing overtreatment in DCIS: What should physicians do now? JNCI: Journal of the National Cancer Institute 2015; 107(1−2). doi.org/10.1093/jnci/djv290.
Morrow M, Van Zee K, Solin L, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016;6(5):287−295. doi:0.1016/j.prro.2016.06.011.
Kuerer H, Smith B, Mariana Chavez-MacGregor M. DCIS margins and breast conservation: MD Anderson cancer center multidisciplinary practice guidelines and outcomes. J Cancer 2017;8(14):2653−2662. doi:10.7150/jca.20871.
Wadsten C, Garmo H Fredriksson, et al Risk of death from breast cancer after treatment for ductal carcinoma in situ. Br J Surg. 2017;(104):1506−1513. doi:10.1002/bjs.10589.
Worni M, Akushevich I, Greenup R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. JNCI 2015;(107):1−10 djv263.
Shiyanbola O, Sprague B, Hampton J, et al. Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. Cancer 2016;122(18):2810–2818. doi:10.1002/cncr.30105.
Moore KH, Sweeney KJ, Wilson ME, et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann Surg Oncol. 2007;(10):2911−2917. doi:10.1245/s10434-007-9414-8.
Lyman G, Giuliano A, Somerfield M et al American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;(23):7703−7720. doi:10.1200/JCO.2005.08.001.
Lyman G, Temin S, Edge S, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014; (32):1365−1383. doi:10.1200/JCO.2013.54.1177.
Ramzi S, Najeeb, E Coulthard E, et al. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good? Breast Cancer Res Treat. 2020;(182):47−54. doi:10.1007/s10549-020-05690-7.
Keerthi GK Ductal carcinoma in situ: How much is too much? Cancer 2016;(122):2780−2782. doi:10.1002/cncr.30107.
Muhsen S, Barrio A, Miller M, et al. Outcomes for women with minimal-volume ductal carcinoma In situ completely excised at core biopsy. Ann of Surg Oncol. 2017;(24):3888−3895. doi:10.1245/s10434-017-6043-8.
Nielsen M, Jensen J Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women Cancer 1984;(54):612−615. doi:10.1002/1097-0142(1984)54:4<612:aid-cncr2820540403>3.0.co;2-b.
Ernster V, Barckay J Kerlikowske K. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;(160):953–958. doi:10.1001/archinte.160.7.953.
Van Zee K, Subhedar P, Olcese C, et al. Relationship between margin width and recurrence of ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg. 2015;(262):623–631. doi:10.1097/SLA.0000000000001454.
Solin L, Gray R, Hughes L, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;(33):3938−3944. doi:10.1200/JCO.2015.60.8588.
van Zee K, Liberman L, Samli B, at al. Long term follow‐up of women with ductal carcinoma in situ treated with breast‐conserving surgery. Cancer 1999;(86):1757−1767. doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1757.
Hwang E, Samli B, Tran K, et al. Volume of resection in patients treated with breast conservation for ductal carcinoma in situ, Ann Surg Oncol. 1998; (8):757−63. doi:10.1007/BF02303488.
Zhang B, Coopey S, Gadd M, et al. Trends in unilateral and contralateral prophylactic mastectomy use in ductal carcinoma in situ of the breast: Patterns and predictors. Ann Surg Oncol. 2019;(26):3863–3873. doi.org/10.1245/s10434-019-07628-w.
Gatěk J, Duben J, Hnátek L, et al. Chirurgická terapie duktálního karcinomu in situ. Rozhl Chir. 2004;83(11):597−603.